Dr. Ji's lab Logo

 

Drug Discovery Patents

1.          “O2-aryl substituted diazeniumdiolates and use thereof,” J.E. Saavedra, L.K. Keefer, A. Srinivasan, C. Bogdan, W.G. Rice, and X. Ji, Australia Patent 733590 (2001).

2.          O2-arylated or O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O2-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates,” J.E. Saavedra, L.K. Keefer, A. Srinivasan, C. Bogdan, W.G. Rice, and X. Ji, US Patent 6610660 (2003).

3.          “O2-arylated or O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O2-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates,” J.E. Saavedra, L.K. Keefer, A. Srinivasan, W.G. Rice, and X. Ji, European (Belgium, France, Ireland, Italy, Switzerland, and United Kingdom) Patent 0929538 (2004).

4.          “O2-arylated or O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O2-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates,” J.E. Saavedra, C. Bogdan, L.K. Keefer, and X. Ji, Germany Patent 69731758.7-0 (2005).

5.          “O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates,” J.E. Saavedra, L.K. Keefer, A. Srinivasan, W.G. Rice, and X. Ji, US Divisional Patent 6911433 (2005).

6.          “O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates,” J.E. Saavedra, L.K. Keefer, A. Srinivasan, W.G. Rice, and X. Ji, US Divisional Patent 7081524 (2006).

7.          “O2-arylated or O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O2-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates,” J.E. Saavedra, C. Bogdan, L.K. Keefer, and X. Ji, Japan Patent 4285775 (2009).

8.          “O2-arylated or O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O2-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates,” J.E. Saavedra, C. Bogdan, L.K. Keefer, and X. Ji, Canada Patent 2266908 (2010).

9.          “O2-arylated or O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O2-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates,” J.E. Saavedra, C. Bogdan, L.K. Keefer, and X. Ji, Japan Divisional Patent 5015903 (2012).

10.       “O2-arylated or O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O2-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates,” J.E. Saavedra, C. Bogdan, L.K. Keefer, and X. Ji, Canada Divisional Patent 2705474 (2013).

11.       “O2-arylated or O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O2-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates,” J.E. Saavedra, L.K. Keefer, A. Srinivasan, W.G. Rice, and X. Ji, European (France, Germany, and United Kingdom) Divisional Patent 1439187 (2013).

12.       “Linked purine pterin HPPK inhibitors useful as antibacterial agents,” G. Shi, G. Shaw, and X. Ji, US Patent 9029344 (2015).

13.       “PARP inhibitor/NO donor dual prodrugs as anticancer agents,” A. Maciag, J. Saavedra, L. Keefer, X. Ji, and V. Kumari, US Patent 9168266 (2015).

14.       “Linked puring pterin HPPK inhibitors useful as antibacterial agents,” G. Shi, G. Shaw, and X. Ji, US Divisional Patent 9453019(2016).

15.       “Irreversible allosteric inhibitors of ubiquitin-conjugating enzyme Ube2g2 useful as antimetastatic agents,” X. Ji, G. Shi, and C. Wang, US Provisional Application Serial No. 62/325,610 (04/21/2016).

16.       HPPK inhibitors useful as antibacterial agents,” X. Ji, G. Shi, and G. Shaw, US Provisional Application Serial No. (10/11//2016).



Home Site Map Contact Disclaimer Viewing Files NCI-Frederick NCI-CCR